Vaborem

Pays: Union européenne

Langue: anglais

Source: EMA (European Medicines Agency)

Achète-le

Ingrédients actifs:

meropenem trihydrate, vaborbactam

Disponible depuis:

Menarini International Operations Luxembourg S.A.

Code ATC:

J01DH

DCI (Dénomination commune internationale):

meropenem, vaborbactam

Groupe thérapeutique:

Antibacterials for systemic use,

Domaine thérapeutique:

Urinary Tract Infections; Bacteremia; Bacterial Infections; Respiratory Tract Infections; Pneumonia; Pneumonia, Ventilator-Associated

indications thérapeutiques:

Vaborem is indicated for the treatment of the following infections in adults:Complicated urinary tract infection (cUTI), including pyelonephritisComplicated intra-abdominal infection (cIAI)Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Vaborem is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Descriptif du produit:

Revision: 7

Statut de autorisation:

Authorised

Date de l'autorisation:

2018-11-20

Notice patient

                                25
B. PACKAGE LEAFLET
26
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
VABOREM 1 G/1 G POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
meropenem/vaborbactam
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or nurse.
-
If you get any side effects, talk to your doctor or nurse. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Vaborem is and what it is used for
2.
What you need to know before you are given Vaborem
3.
How you will be given Vaborem
4.
Possible side effects
5.
How to store Vaborem
6.
Contents of the pack and other information
1.
WHAT VABOREM IS AND WHAT IT IS USED FOR
WHAT VABOREM IS
Vaborem is an antibiotic medicine that contains two active substances:
meropenem and vaborbactam.
•
Meropenem belongs to group of antibiotics called “carbapenems”. It
can kill many types of bacteria
by preventing them from building the protective walls that surround
their cells.
•
Vaborbactam is a “beta lactamase inhibitor”. It blocks the action
of an enzyme that allows some
bacteria to resist the action of meropenem. This helps meropenem kill
some bacteria that it cannot
kill on its own.
WHAT VABOREM IS USED FOR
Vaborem is used in adults to treat certain serious bacterial
infections:
•
of the bladder or kidneys (urinary tract infections)
•
of the stomach and gut (intra-abdominal infections)
•
of the lungs (pneumonia)
It is also used to treat infections
•
of the blood associated with any of the infections mentioned above
•
caused by bacteria that other antibiotics may not be able to kill
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN VABOREM
YOU MUST NOT BE GIVEN VABOREM
IF
•
you are allergic to meropenem, vaborbactam or the other ingredients of
this medicine (listed in
section 6).
•
you are allergic to other carbapenem antibiotics (the group to which
merope
                                
                                Lire le document complet
                                
                            

Résumé des caractéristiques du produit

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Vaborem 1 g/1 g powder for concentrate for solution for infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each vial contains meropenem trihydrate equivalent to 1 g meropenem,
and 1 g vaborbactam.
After reconstitution, 1 ml of the solution contains 50 mg meropenem
and 50 mg vaborbactam (see section
6.6).
Excipient with known effect:
Each vial contains 10.9 mmol of sodium (approximately 250 mg).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for concentrate for solution for infusion (powder for
concentrate).
White to light yellow powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Vaborem is indicated for the treatment of the following infections in
adults (see sections 4.4 and 5.1):
•
Complicated urinary tract infection (cUTI), including pyelonephritis
•
Complicated intra-abdominal infection (cIAI)
•
Hospital-acquired pneumonia (HAP), including ventilator associated
pneumonia (VAP).
Treatment of patients with bacteraemia that occurs in association
with, or is suspected to be associated
with, any of the infections listed above.
Vaborem is also indicated for the treatment of infections due to
aerobic Gram-negative organisms in
adults with limited treatment options (see sections 4.2, 4.4 and 5.1).
Consideration should be given to official guidance on the appropriate
use of antibacterial agents.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Vaborem should be used to treat infections due to aerobic
Gram-negative organisms in adult patients with
limited treatment options only after consultation with a physician
with appropriate experience in the
management of infectious diseases (see sections 4.4 and 5.1).
Posology
3
Table 1 shows the recommended intravenous dose for patients with a
creatinine clearance
(CrCl) ≥40 ml/min (see sections 4.4 and 5.1).
TABLE 1:
RECOMMENDED INTRAVENOUS DOSE FOR PATIENTS WITH A CREATININE CLEARANCE
(CRCL) ≥40 ML/MIN
1
Type of infection
Dose of Vaborem
(meropenem/
v
                                
                                Lire le document complet
                                
                            

Documents dans d'autres langues

Notice patient Notice patient bulgare 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation bulgare 18-12-2018
Notice patient Notice patient espagnol 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation espagnol 18-12-2018
Notice patient Notice patient tchèque 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation tchèque 18-12-2018
Notice patient Notice patient danois 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation danois 18-12-2018
Notice patient Notice patient allemand 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation allemand 18-12-2018
Notice patient Notice patient estonien 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation estonien 18-12-2018
Notice patient Notice patient grec 26-07-2023
Notice patient Notice patient français 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation français 18-12-2018
Notice patient Notice patient italien 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation italien 18-12-2018
Notice patient Notice patient letton 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation letton 18-12-2018
Notice patient Notice patient lituanien 26-07-2023
Notice patient Notice patient hongrois 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation hongrois 18-12-2018
Notice patient Notice patient maltais 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation maltais 18-12-2018
Notice patient Notice patient néerlandais 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation néerlandais 18-12-2018
Notice patient Notice patient polonais 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation polonais 18-12-2018
Notice patient Notice patient portugais 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation portugais 18-12-2018
Notice patient Notice patient roumain 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation roumain 18-12-2018
Notice patient Notice patient slovaque 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation slovaque 18-12-2018
Notice patient Notice patient slovène 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation slovène 18-12-2018
Notice patient Notice patient finnois 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation finnois 18-12-2018
Notice patient Notice patient suédois 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation suédois 18-12-2018
Notice patient Notice patient norvégien 26-07-2023
Notice patient Notice patient islandais 26-07-2023
Notice patient Notice patient croate 26-07-2023
Rapport public d'évaluation Rapport public d'évaluation croate 18-12-2018

Rechercher des alertes liées à ce produit

Afficher l'historique des documents